Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/4237
| Subject | Predicate | Object | Context |
|---|---|---|---|
| dailymed-drugs:4237 | rdf:type | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:4237 | rdf:type | dailymed-instance:drugs | lld:dailymed |
| dailymed-drugs:4237 | rdfs:label | Plasma-Lyte M and Dextrose (Injection, Solution) | lld:dailymed |
| dailymed-drugs:4237 | dailymed-instance:dosage | As directed by a physician. Dosage is dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. All injections in Viaflex' plastic containers are intended for intravenous administration using sterile equipment. As reported in the literature, the dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low weight infants, because of the increased risk of hyperglycemia/hypoglycemia. Additives may be incompatible. Complete information is not available. Those additives known to be incompatible should not be used. Consult with pharmacist, if available. If, in the informed judgment of the physician, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. Do not store solutions containing additives. | lld:dailymed |
| dailymed-drugs:4237 | dailymed-instance:descripti... | Plasma-Lyte' M and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 2, USP) is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment and caloric supply in a single dose container for intravenous administration. Each 100 mL contains 5 g Dextrose Hydrous, USP*, 161 mg Sodium Acetate Trihydrate, USP (CHNaO���3HO); 138 mg Sodium Lactate (CHNaO), 119 mg Potassium Chloride, USP (KCl), 94 mg Sodium Chloride, USP (NaCl), 37 mg Calcium Chloride, USP (CaCl���2HO), and 30 mg Magnesium Chloride, USP (MgCl���6HO). It contains no antimicrobial agents. The pH is 5.0 (4.0 to 6.5). The pH is adjusted with hydrochloric acid. Plasma-Lyte' M and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 2, USP) administered intravenously has value as a source of water, electrolytes, and calories. One liter has an ionic concentration of 40 mEq sodium, 16 mEq potassium, 5 mEq calcium, 3 mEq magnesium, 40 mEq chloride, 12 mEq acetate, and 12 mEq lactate. The osmolarity is 377 mOsmol/L (calc). Normal physiologic osmolarity range is approximately 280 to 310 mOsmol/L. Administration of substantially hypertonic solutions (���600 mOsmol/L) may cause vein damage. The caloric content is 180 kcal/L. The Viaflex' plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146' Plastic). The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials. | lld:dailymed |
| dailymed-drugs:4237 | dailymed-instance:clinicalP... | Plasma-Lyte' M and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 2, USP) has value as a source of water, electrolytes, and calories. It is capable of inducing diuresis depending on the clinical condition of the patient. Plasma-Lyte' M and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 2, USP) produces a metabolic alkalinizing effect. Acetate and lactate ions are metabolized ultimately to carbon dioxide and water, which requires the consumption of hydrogen cations. | lld:dailymed |
| dailymed-drugs:4237 | dailymed-instance:activeIng... | dailymed-ingredient:Dextros... | lld:dailymed |
| dailymed-drugs:4237 | dailymed-instance:contraind... | Solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products. | lld:dailymed |
| dailymed-drugs:4237 | dailymed-instance:supply | Plasma-Lyte' M and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 2, USP) in Viaflex' plastic containers is available as shown below: Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (25��C); brief exposure up to 40��C does not adversely affect the product. | lld:dailymed |
| dailymed-drugs:4237 | dailymed-instance:activeMoi... | dailymed-ingredient:dextros... | lld:dailymed |
| dailymed-drugs:4237 | dailymed-instance:inactiveI... | dailymed-ingredient:Water | lld:dailymed |
| dailymed-drugs:4237 | dailymed-instance:inactiveI... | dailymed-ingredient:Hydroch... | lld:dailymed |
| dailymed-drugs:4237 | dailymed-instance:genericMe... | Sodium chloride, potassium chloride, magnesium chloride, calcium chloride, sodium acetate, sodium lactate and dextrose | lld:dailymed |
| dailymed-drugs:4237 | dailymed-instance:fullName | Plasma-Lyte M and Dextrose (Injection, Solution) | lld:dailymed |
| dailymed-drugs:4237 | dailymed-instance:adverseRe... | Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation, and hypervolemia. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary. | lld:dailymed |
| dailymed-drugs:4237 | dailymed-instance:warning | Plasma-Lyte' M and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 2, USP) should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states in which there exists edema with sodium retention. Plasma-Lyte' M and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 2, USP) should be used with great care, if at all, in patients with hyperkalemia, severe renal failure, and in conditions in which potassium retention is present. Plasma-Lyte' M and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 2, USP) should be used with great care in patients with metabolic or respiratory alkalosis. The administration of lactate or acetate ions should be done with great care in those conditions in which there is an increased level or an impaired utilization of these ions, such as severe hepatic insufficiency. Plasma-Lyte' M and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 2, USP) should not be administered simultaneously with blood through the same administration set because of the likelihood of coagulation. The intravenous administration of Plasma-Lyte' M and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 2, USP) can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states, or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentrations of the injection. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of the injection. In patients with diminished renal function, administration of Plasma-Lyte' M and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 2, USP) containing sodium or potassium ions may result in sodium or potassium retention. Plasma-Lyte' M and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 2, USP) is not for use in the treatment of lactic acidosis. | lld:dailymed |
| dailymed-drugs:4237 | dailymed-instance:indicatio... | Plasma-Lyte' M and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 2, USP) is indicated as a source of water, electrolytes, and calories or as an alkalinizing agent. | lld:dailymed |
| dailymed-drugs:4237 | dailymed-instance:represent... | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:4237 | dailymed-instance:routeOfAd... | http://www4.wiwiss.fu-berli... | lld:dailymed |
| dailymed-drugs:4237 | dailymed-instance:name | Plasma-Lyte M and Dextrose | lld:dailymed |
| http://www4.wiwiss.fu-berli... | dailymed-instance:producesD... | dailymed-drugs:4237 | lld:dailymed |